Skip to main content

Table 4 Treatments and outcomes of the NEC and MiNEN patients

From: Long-term surgical outcomes of gastric neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasms

Patient

Diagnosis

Surgical procedure

pStage

NAC

Adjuvant chemotherapy

REC

OS (months)

RFS (months)

Outcome

Cause of death

1

LCNEC

TG

IIB

None

S-1

None

93.8

93.8

Alive

-

2

MiNEN

TG

IA

None

None

None

99.9

99.9

Alive

-

3

LCNEC

TG

IIB

None

None

liver

37.3

6.9

Dead

Cancer

4

MiNEN

DG

IIIB

None

S-1

None

99.7

99.6

Alive

-

5

LCNEC

TG

IIIC

None

None

LN

63.7

5.4

Dead

Cancer

6

LCNEC

TG

IIB

None

S-1

None

129

129

Alive

-

7

LCNEC

DG

IA

None

None

None

24.6

24.6

Alive

-

8

MiNEN

TG

IB

None

None

none

67.4

67.4

Alive

-

9

MiNEN

TG

IIIA

none

None

P

39.9

18.2

Dead

Cancer

10

LCNEC

TG

IIIA

None

S-1

None

68.7

68.7

Alive

-

11

MiNEN

PG

IA

None

None

None

77.3

77.3

Alive

-

12

MiNEN

DG

IIIC

None

None

P

72.1

6.67

Dead

Cancer

13

LCNEC

TG

IIIB

None

CDDP + CPT-11

None

12

12

Alive

-

  1. LCNEC, large cell neuroendocrine carcinoma; MiNEN, mixed neuroendocrine-non-neuroendocrine neoplasm; TG, total gastrectomy; DG, distal gastrectomy; PG, proximal gastrectomy; S-1, Tegafur/gimeracil/oteracil; CDDP, cisplatin; CPT-11, irinotecan; pStage, pathological stage; NAC, neoadjuvant chemotherapy; REC, recurrence; OS, overall survival; RFS, recurrence-free survival; LN, lymph nodes; P, peritoneum